Stocktwits on MSN

CADL retail bulls see buyout potential as key cancer data catalyst approaches

Candel is set to submit a Biologics License Application to the U.S. Food and Drug Administration by the fourth quarter of 2026. ・The Phase 3 trial, which met its primary endpoint, included 745 ...
ascopubs.org

Usage of the National Cancer Institute Cancer Research Data Commons by Researchers: A Scoping Review of the Literature

Improving Diagnosis and Care for Patients With Sarcoma: Do Real-World General Practitioners Data and Prospective Data Collections Have a Place Next to Clinical Trials? A thorough literature search was ...
ascopubs.org

Advancements in Interoperability: Achieving Anatomic Pathology Reports That Adhere to International Standards and Are Both Human-Readable and Readily Computable

Over the past 50 years, multiple pathology organizations worldwide have evolved in cancer histopathology reporting from subjective, narrative assessments to structured, synoptic formats using ...
Bloomberg L.P.

GSK, iTeos Lung Cancer Data Set to Reignite Hope for Drug Class

Early data from GSK Plc and iTeos Therapeutics’ mid-stage trial of a lung cancer medicine looks set to renew cautious optimism around a class of immunotherapy drugs that has suffered a series of ...
CNBC

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. I'm back in ...